24 Results for "

NB4 cell

" in MedChemExpress (MCE) Product Catalog:
Products (24)

24 Results for "NB4 cell" in MCE Product Catalog:

45
45 Publications Verification
Cat. No.: HY-N0176
CAS No.: 71939-50-9
Synonyms: Dihydroqinghaosu; β-Dihydroartemisinin; Artenimol
Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...
25
25 Cited Publications
Cat. No.: HY-14909
CAS No.: 218600-44-3
Purity:  99.50%
Synonyms: CDDO; RTA 401
Bardoxolone (CDDO; RTA 401) is a Nrf2 activator. Bardoxolone shows anti-SARS-CoV-2 3CLpro with IC50 of 27.99 μM. Bardoxolone activates the Nrf2 pathway and inhibits the NF-κB pathway. Bardoxolone can induce cells differentiation, apoptosis and shows antiproliferative activity against cancer cells. Bardoxolone can increase ROS and decrease intracellular GSH levels. Bardoxolone inhibits Z-VAD-FMK (HY-16658B)-induced necroptosis. Bardoxolone can be used for the research of cancer, inflammation and infection, such as SARS-CoV infection and glioblastoma .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-N0105
CAS No.: 478-43-3
Synonyms: Rheic Acid; Rhubarb yellow; Monorhein
Rhein is an anthraquinone compound with anti-inflammatory, antioxidant, and anti-cancer effects [1] .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-19350
CAS No.: 537034-17-6
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-N0620
CAS No.: 102841-43-0
Mulberroside C is one of the main bioactive components in white mulberry (Morus alba L.). Mulberroside C exhibits antiplatelet, antiviral and neutrophil-regulating activities, and binds to EV-A71 VP1 with a Kd value of 1.289 nM. Mulberroside C reduces the phosphorylation level of ERK, promotes the phosphorylation of IP3RI at the Ser 1756 site, and decreases calcium influx and calcium mobilization. Mulberroside C inhibits the expression of P-selectin (P-selectin). Mulberroside C upregulates the cyclic nucleotide signaling pathway in human platelets. Mulberroside C binds to IL-23R, upregulates the expression of G-CSF, GM-CSF and RASGRP1, and activates the RAS/ERK signaling pathway. Mulberroside C promotes neutrophil maturation, accelerates the recovery of leukopenia, and enhances the antibacterial activity of neutrophils. Mulberroside C inhibits the replication of hepatitis C virus in replicon cells. Mulberroside C prevents the uncoating and genome release of EV-A71, and inhibits the synthesis of viral proteins and RNA. Mulberroside C can be used in studies related to thrombosis-mediated cardiovascular diseases, chemotherapy- and radiotherapy-induced leukopenia, hepatitis C virus infection, and hand, foot and mouth disease .
loading...
    loading...
Cat. No.: HY-N0176R
CAS No.: 71939-50-9
Synonyms: Dihydroqinghaosu (Standard); β-Dihydroartemisinin (Standard); Artenimol (Standard)
Dihydroartemisinin (Standard) (Dihydroqinghaosu (Standard)) is the analytical standard of Dihydroartemisinin (HY-N0176). This product is intended for research and analytical applications. Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...
Cat. No.: HY-174979
CAS No.: 3084407-00-8
Dac590 is an orally active and selective obesity-associated protein (FTO) inhibitor with an IC50 of 6.06 nM. Dac590 shows highly selective over ALKBH5 and ALKBH3. Dac590 suppresses oncogenic FTO signaling, induces myeloid differentiation, G1-phase cell cycle arrest, and apoptosis in acute myeloid leukemia (AML) cells. Dac590 inhibits xenograft tumor growth and prolongs survival in acute myeloid leukemia mouse models with no observed toxicity. Dac590 can be used for the research of AML .
loading...
    loading...
Cat. No.: HY-127130
CAS No.: 87099-85-2
Research Areas:  

Infection Cancer

Spicamycin, an adenine nucleoside antibiotic with antifungal and antitumor activities. Spicamycin is also a potent inducer of differentiation of myeloid leukemia cells. Spicamycin induces apoptosis in NB4 cells via down-regulation of Bcl-2 expression and modulation of PML protein .
loading...
    loading...
Cat. No.: HY-N10764
CAS No.: 116368-90-2
Acetylexidonin is a diterpenoid compound with anti-inflammation and cancer activity. Acetylexidonin inhibits tumor cells with IC50s of 3.69 μM (NB4) and 26.22 μM (SHSY5Y), respectively .
loading...
    loading...
Cat. No.: HY-162658
Target:  

HDAC Apoptosis

Research Areas:  

Cancer

Leuxinostat is an inhibitor for HDAC with IC50 of 30 nM for hHDAC6. Leuxinostat inhibits the proliferation of cells THP1, K562, U937 and MEK1, induces apoptosis in leukemia cells NB4 and MOLT-4. Leuxinostat inhibits the expansion of hematopoietic stem cells and exhibits antileukemic activity in zebrafish models .
loading...
    loading...
Cat. No.: HY-118761
CAS No.: 13100-69-1
Synonyms: 5,6-epoxy atRA; 5,6-epoxy RA
Target:  

RAR/RXR

Research Areas:  

Metabolic Disease

all-trans-5,6-epoxy Retinoic acid (5,6-epoxy RA) is an agonist of all isoforms of the retinoic acid receptor (RAR; EC50s=77, 35, and 4 nM for RARα, RARβ, and RARγ, respectively). 5,6-epoxy RA (1 μM) also induces growth arrest of MCF-7 and NB4 cells in vitro. It is a natural metabolite of all-trans retinoic acid, which is a metabolite of vitamin A.
loading...
    loading...
Cat. No.: HY-W103792
CAS No.: 13026-23-8
Target:  

HDAC

Research Areas:  

Cancer

4-Phenylcinnamic acid is a weak HDAC2 inhiibitor (IC50 > 5 μM). 4-Phenylcinnamic acid has weak cell growth inhibition against tumor cells .
loading...
    loading...
Cat. No.: HY-144755
CAS No.: 2771425-46-6
Target:  

Histone Demethylase

Research Areas:  

Cancer

MC2652 (compound 1a) is a potent LSD1 inhibitor. MC2652 displays high inhibiting effects in MV4-11 and NB4 leukaemia cells. MC2652 shows antiproliferative activity against prostate cancer LNCaP cells .
loading...
    loading...
Cat. No.: HY-13906
CAS No.: 1009815-87-5
Synonyms: (+)-Largazole
Largazole ((+)-Largazole) is an orally active, blood-brain barrier-permeable class I histone deacetylase (HDAC) inhibitor with in vivo anticancer activity and osteogenic efficacy. As a prodrug, Largazole hydrolyzes to Largazole thiol (HY-170890), which has a Ki value of 0.07 nM against human HDAC2. Largazole regulates the cell cycle, induces apoptosis, upregulates tumor suppressors and osteoblast differentiation markers, inhibits osteoclast formation, and upregulates neuroprotection-related genes. Largazole can be used in the research of various cancers including colorectal cancer, as well as neurodegenerative diseases .
loading...
    loading...
Cat. No.: HY-172399
FTO-IN-14 (Compound F97) is the inhibitor for the RNA demethylase Fat mass and obesity-associated protein FTO with IC50 of 0.45 μM. FTO-IN-14 regulates the protein expression of ASB2, RARA and MYC. FTO-IN-14 exhibits antiproliferative activity in AML cancer cells (IC50 for MOLM13, NB4, HEL, OCI-AML3, MV4-11 and MONOMAC6 is 0.7-5.5 μM), induces apoptosis in NB4 cell. FTO-IN-14 exhibits antitumor activity in mouse NB4 xenograft models .
loading...
    loading...
Cat. No.: HY-W965550
CAS No.: 83800-90-2
Target:  

Apoptosis

Research Areas:  

Cancer

Apoptosis inducer 40 is an apoptosis inducer. Apoptosis inducer 40 exhibits potent cytotoxic effects against jurkat and NB4 cells with IC50 values of 4.5 μM and 3.6μM. Apoptosis inducer 40 induces apoptosis and arrests cell cycle. Apoptosis inducer 40 can be used for the research of cancer, such as acute myeloid leukemia (AML) .
loading...
    loading...
Cat. No.: HY-149522
CAS No.: 3034883-70-7
Target:  

Bcl-2 Family Apoptosis

Research Areas:  

Cancer

BCL6-IN-10 (Compound WK499) is a BCL6 inhibitor. BCL6-IN-10 interrupts the binding of BCL6 to SMRT protein. BCL6-IN-10 induces cell apoptosis, cell cycle arrest and DNA damage. BCL6-IN-10 inhibits AML cell proliferation (IC50s: 0.91, 1.63, 1.026, 7.42, 0.87, 0.85μM for OCl-AML3, THP1, MOLM13, HL60, KG1, NB4 cell respectively) .
loading...
    loading...
Cat. No.: HY-168483
CAS No.: 687600-25-5
FTO-IN-13 (compound 8t) is a potent FTO inhibitor. FTO-IN-13 shows antiproliferative activity. FTO-IN-13 induces apoptosis. FTO-IN-13 decreases the protein expression of Bcl-2 and Caspase 3 active. FTO-IN-13 decreases MYC and CEBPA gene expression. FTO-IN-13 shows anticancer activity .
loading...
    loading...
Cat. No.: HY-N0176S
CAS No.: 176774-98-4
Synonyms: Dihydroqinghaosu-d3; β-Dihydroartemisinin-d3; Artenimol-d3
Dihydroartemisinin-d3 (Dihydroqinghaosu-d3) is the d3-labeled Dihydroartemisinin (HY-N0176). Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...
Cat. No.: HY-N0176S3
Synonyms: Dihydroqinghaosu-d5; β-Dihydroartemisinin-d5; Artenimol-d5
Dihydroartemisinin-d5 (Dihydroqinghaosu-d5) is the d5-labeled Dihydroartemisinin (HY-N0176). Dihydroartemisinin is an orally active metabolite of rtemisinin (HY-B0094) and antimalarial agent. Dihydroartemisinin induces Autophagy by inhibiting NF-κB activation. Dihydroartemisinin promotes ROS accumulation. Dihydroartemisinin exhibits anticancer activity in esophageal cancer cells. Dihydroartemisinin shows schistosomicidal activity against juvenile and adult worms of Schistosoma japonicum, reduces worm burden, and displays antiparasitic activity. Dihydroartemisinin can be used in research related to multiple myeloma, promyelocytic leukemia, esophageal cancer, and Schistosoma japonicum infection .
loading...
    loading...